Clinical guideline
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0
J Immunother Cancer · 2026
Studies and guidelines: Kidney cancer
29 items with a structured summary · Kidney cancer: the complete guide
Clinical guideline
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2025 Update
Eur Urol · 2025
Clinical guideline
Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Annals of Oncology · 2024
Clinical guideline
Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
J Natl Compr Canc Netw · 2022
Clinical guideline
Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-Up: AUA Guideline: Part I
Journal of Urology · 2021
Individualised counselling and managementOverall approach to the patient
Clinical guideline
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update
Eur Urol · 2022
Clinical trial · Phase 3
Adjuvant pembrolizumab for the treatment of clear cell renal cell carcinoma: five-year results from the phase III KEYNOTE-564 study
Ann Oncol · 2026
60.9% vs 52.2%5-year disease-free survival
Clinical trial · Phase 3
Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma
N Engl J Med · 2026
80.7% vs 73.7%24-month disease-free survival
Clinical trial · Phase 3
Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial
Lancet · 2026
14.8 vs 10.7 monthsMedian progression-free survival
Clinical trial · Phase 3
Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial
Ann Oncol · 2026
46.5 vs 35.5 monthsMedian overall survival
Clinical trial · Phase 3
Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial
Nat Med · 2025
HR 0.84Overall survival
Clinical trial · Phase 3
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study
JCO · 2024
0.79 (95% CI 0.63–0.99)Overall survival (OS) — hazard ratio
Review article
Epidemiology of Renal Cell Carcinoma: 2022 Update
European Urology · 2022
Still risingTrend in kidney cancer incidence
Clinical trial · Phase 3
Sunitinib Alone or After Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Is There Still a Role for Cytoreductive Nephrectomy?
Eur Urol · 2021
HR 0.97Overall survival (all patients)
Clinical trial · Phase 2
Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
The Lancet Oncology · 2015
14.6 months (95% CI 5.9–20.1) vs 5.5 months (3.5–7.1)Median progression-free survival: lenvatinib + everolimus vs everolimus
Clinical trial · Phase 3
A Prospective, Randomised EORTC Intergroup Phase 3 Study Comparing the Oncologic Outcome of Elective Nephron-Sparing Surgery and Radical Nephrectomy for Low-Stage Renal Cell Carcinoma
European Urology · 2011
9.3 yearsMedian follow-up
Observational study
Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
JCO · 2009
22 monthsMedian overall survival in the whole population
Clinical trial · Phase 3
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
The Lancet · 2007
10.2 months vs 5.4 months (bevacizumab + interferon vs placebo + interferon)Median progression-free survival
Clinical trial · Phase 3
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
N Engl J Med · 2007
5.5 months vs 2.8 months (sorafenib vs placebo)Median progression-free survival (January 2005)
Clinical trial · Phase 3
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial
Ann Oncol · 2026
HR 0.69Overall survival (intermediate/poor risk)
Clinical trial · Phase 1
A neoantigen vaccine generates antitumour immunity in renal cell carcinoma
Nature · 2025
0 of 9 patientsKidney cancer recurrence
Clinical trial · Phase 3
Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma
N Engl J Med · 2024
24.0% vs 8.3%18-month progression-free survival
Clinical trial · Phase 3
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma
N Engl J Med · 2024
77.3% vs 68.1%24-month disease-free survival (first interim analysis, 2021)
Clinical trial · Phase 3
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma
N Engl J Med · 2021
24.1 monthsFollow-up (median time from randomisation to data cut-off)
Clinical trial · Phase 3
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
N Engl J Med · 2021
23.9 vs 9.2 monthsMedian progression-free survival (lenvatinib + pembrolizumab)
Clinical trial · Phase 3
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
N Engl J Med · 2021
16.6 vs 8.3 monthsMedian progression-free survival
Clinical trial · Phase 3
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
N Engl J Med · 2019
89.9% vs 78.3%12-month overall survival
Clinical trial · Phase 3
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
N Engl J Med · 2018
75% vs 60%18-month overall survival (intermediate/poor risk)
Clinical trial · Phase 3
Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma
N Engl J Med · 2018
HR 0.89Overall survival (HR, sunitinib alone vs nephrectomy + sunitinib)
Nothing found.